Senseera Secures $7.1M Seed Funding for Biopsy Platform

Senseera, a Jerusalem-based biotech company, has secured $7.1 million in seed funding, led by Lightspeed Venture Partners, to advance its GEM BIOMARKERS liquid biopsy platform, which utilizes cfChIP-seq technology. This innovative platform offers biopsy-level precision through a simple blood test, enabling the analysis of gene expression and cell states, which could revolutionize the diagnosis and management of liver diseases and other conditions. Current diagnostic methods often involve invasive procedures, resulting in delayed diagnoses and poor patient care, which Senseera aims to address. The funding will support the development of a next-generation liver transplant rejection test and facilitate clinical trials and partnerships with global biopharmaceutical companies. Senseera's technology is grounded in decades of research and has been validated with data from over 20,000 human samples, positioning it to enhance drug development in oncology and immunology as well. CEO Dr. Ronen Sadeh emphasized that this funding is a significant milestone in transforming diagnostics for liver diseases and beyond.